Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240021808> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4240021808 endingPage "TPS767" @default.
- W4240021808 startingPage "TPS767" @default.
- W4240021808 abstract "TPS767 Background: C inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER), and may promote an immune-permissive tumor environment, resulting in enhanced response to immune checkpoint inhibitors. C has shown preliminary clinical activity and tolerability in combination with the PD-1 inhibitor N and as part of a triplet combination with N and the CTLA-4 inhibitor I in pts with aRCC (Nadal et al. ASCO 2018). C is approved for pts with aRCC, and N+I is approved as a combination therapy in pts with previously untreated aRCC of intermediate or poor risk. We present the study design of a phase 3 trial of C+N+I vs N+I in previously untreated pts with aRCC of IMDC intermediate or poor risk (NCT03937219). Methods: This randomized, double-blind, controlled phase 3 study evaluates the efficacy and safety of C+N+I vs N+I in previously untreated pts with IMDC intermediate or poor risk aRCC. Eligible pts are randomized 1:1 to receive C+N+I or N+I in combination with placebo, stratified by IMDC prognostic score and geographic region. Pts receive C (40 mg oral QD) + N (3 mg/kg IV Q3W) x 4 doses + I (1 mg/kg IV Q3W) x 4 doses, followed by C (40 mg oral QD) + N (480 mg IV flat dose Q4W). Control pts receive C-matched placebo and the same treatment regimen for N+I as the experimental arm. N will be administered for a maximum of 2 years. Eligibility criteria include histologically confirmed metastatic or aRCC with a clear cell component, intermediate or poor risk RCC per IMDC criteria, measurable disease per RECIST 1.1, KPS ≥70%, adequate organ and marrow function and age ≥18 years. Exclusion criteria include prior systemic therapy for aRCC and uncontrolled significant illnesses. The primary endpoint is PFS per RECIST 1.1 by BICR; the secondary endpoint is OS. Additional endpoints include ORR, safety, correlation of biomarkers with outcomes, and pharmacokinetics of C in combination with N+I. The first patient was enrolled in June 2019 and enrollment is ongoing. Clinical trial information: NCT03937219." @default.
- W4240021808 created "2022-05-12" @default.
- W4240021808 creator A5014241516 @default.
- W4240021808 creator A5052504518 @default.
- W4240021808 creator A5059063118 @default.
- W4240021808 creator A5072911394 @default.
- W4240021808 creator A5074162105 @default.
- W4240021808 creator A5087227508 @default.
- W4240021808 date "2020-02-20" @default.
- W4240021808 modified "2023-10-17" @default.
- W4240021808 title "A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk." @default.
- W4240021808 doi "https://doi.org/10.1200/jco.2020.38.6_suppl.tps767" @default.
- W4240021808 hasPublicationYear "2020" @default.
- W4240021808 type Work @default.
- W4240021808 citedByCount "26" @default.
- W4240021808 countsByYear W42400218082020 @default.
- W4240021808 countsByYear W42400218082021 @default.
- W4240021808 countsByYear W42400218082022 @default.
- W4240021808 countsByYear W42400218082023 @default.
- W4240021808 crossrefType "journal-article" @default.
- W4240021808 hasAuthorship W4240021808A5014241516 @default.
- W4240021808 hasAuthorship W4240021808A5052504518 @default.
- W4240021808 hasAuthorship W4240021808A5059063118 @default.
- W4240021808 hasAuthorship W4240021808A5072911394 @default.
- W4240021808 hasAuthorship W4240021808A5074162105 @default.
- W4240021808 hasAuthorship W4240021808A5087227508 @default.
- W4240021808 hasConcept C121608353 @default.
- W4240021808 hasConcept C126322002 @default.
- W4240021808 hasConcept C142724271 @default.
- W4240021808 hasConcept C143998085 @default.
- W4240021808 hasConcept C197934379 @default.
- W4240021808 hasConcept C204787440 @default.
- W4240021808 hasConcept C27081682 @default.
- W4240021808 hasConcept C2777701055 @default.
- W4240021808 hasConcept C2778375690 @default.
- W4240021808 hasConcept C2780030458 @default.
- W4240021808 hasConcept C2781064419 @default.
- W4240021808 hasConcept C2781413609 @default.
- W4240021808 hasConcept C2781433595 @default.
- W4240021808 hasConcept C71924100 @default.
- W4240021808 hasConcept C90924648 @default.
- W4240021808 hasConceptScore W4240021808C121608353 @default.
- W4240021808 hasConceptScore W4240021808C126322002 @default.
- W4240021808 hasConceptScore W4240021808C142724271 @default.
- W4240021808 hasConceptScore W4240021808C143998085 @default.
- W4240021808 hasConceptScore W4240021808C197934379 @default.
- W4240021808 hasConceptScore W4240021808C204787440 @default.
- W4240021808 hasConceptScore W4240021808C27081682 @default.
- W4240021808 hasConceptScore W4240021808C2777701055 @default.
- W4240021808 hasConceptScore W4240021808C2778375690 @default.
- W4240021808 hasConceptScore W4240021808C2780030458 @default.
- W4240021808 hasConceptScore W4240021808C2781064419 @default.
- W4240021808 hasConceptScore W4240021808C2781413609 @default.
- W4240021808 hasConceptScore W4240021808C2781433595 @default.
- W4240021808 hasConceptScore W4240021808C71924100 @default.
- W4240021808 hasConceptScore W4240021808C90924648 @default.
- W4240021808 hasFunder F4320312140 @default.
- W4240021808 hasIssue "6_suppl" @default.
- W4240021808 hasLocation W42400218081 @default.
- W4240021808 hasOpenAccess W4240021808 @default.
- W4240021808 hasPrimaryLocation W42400218081 @default.
- W4240021808 hasRelatedWork W2534538480 @default.
- W4240021808 hasRelatedWork W2788498597 @default.
- W4240021808 hasRelatedWork W3020932086 @default.
- W4240021808 hasRelatedWork W3136608335 @default.
- W4240021808 hasRelatedWork W3152520552 @default.
- W4240021808 hasRelatedWork W3210028029 @default.
- W4240021808 hasRelatedWork W4221029189 @default.
- W4240021808 hasRelatedWork W4226292283 @default.
- W4240021808 hasRelatedWork W4280556106 @default.
- W4240021808 hasRelatedWork W4283751238 @default.
- W4240021808 hasVolume "38" @default.
- W4240021808 isParatext "false" @default.
- W4240021808 isRetracted "false" @default.
- W4240021808 workType "article" @default.